## INSOMNIA

**From the AMERICAN GERIATRICS SOCIETY**

**Geriatrics Evaluation & Management Tools**

AGS Geriatrics Evaluation and Management Tools (Geriatrics E&M Tools) support clinicians and systems that are caring for older adults with common geriatric conditions.

### DEFINITION

Difficulty falling or staying asleep, waking up too early, or experiencing poor-quality nonrestorative sleep; associated with daytime impairment (fatigue, poor concentration, daytime sleepiness, or concerns about sleep).

### BACKGROUND

- Prevalence of 30% in those >65 years old.

### SCREENING

- All geriatric patients should be asked annually about sleep problems.
- Is the person satisfied with his or her sleep?
- Does sleep or fatigue interfere with daytime activities?
- Does the bed partner or others complain of snoring, interrupted breathing, or excessive movements?

### HISTORY OF PRESENT ILLNESS

- Patient sleep log can be helpful.
- Each morning, record: the time spent in bed, the estimated amount of sleep, the number of awakenings, the time of morning awakening, any symptoms that occurred during the night.
- Supplement with information from bed partner, others, and/or validated sleep questionnaire.
- Sleep questionnaires and evaluation tools available from the American Academy of Sleep Medicine website: http://yoursleep.aasmnet.org/EvaluateSleep.aspx

### MEDICATIONS

- Thorough evaluation of medications that can contribute to sleep problems (including over-the-counter).
- Lighter, shorter/fragmented sleep: alcohol, sedatives, cholinesterase inhibitors.
- Nightmares: antidepressants, anti-Parkinson’s agents, antihypertensives, cholinesterase inhibitors.
- Nocturia: diuretics.
- Sedation: clonidine, phenytoin (or insomnia also possible with phenytoin).
- Stimulation: bronchodilators, caffeine, corticosteroids, nicotine, sympathomimetics, antidepressants.

### PHYSICAL EXAM

- Focused physical exam typically including ENT, cardiac, pulmonary, and neurologic systems.

### FURTHER TESTING

- Polysomnography is indicated if a primary sleep disorder is suspected: sleep apnea, narcolepsy, periodic limb movement disorder, violent or unusual behaviors during sleep.
- In-home portable sleep-monitoring systems can be used to screen for sleep apnea.

### NONPHARMACOLOGIC INTERVENTIONS

**Examples of Nonpharmacologic Interventions to Improve Sleep**

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Goal</th>
<th>Brief Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stimulus control</td>
<td>To recondition maladaptive sleep-related behaviors</td>
<td>Patient is instructed to go to bed only when sleepy, not use the bed for eating or watching television, get out of bed if unable to fall asleep, return to bed only when sleepy, get up at same time each morning, not take naps during the day.</td>
</tr>
<tr>
<td>Sleep restriction</td>
<td>To improve sleep efficiency (time asleep over time in bed) by limiting time in bed</td>
<td>Patient first keeps a sleep diary for 1–2 weeks to determine average total daily sleep time, then stays in bed only that amount of time plus 15 minutes; gets up at same time each morning; takes no naps during the day; gradually increases time allowed in bed as sleep efficiency improves.</td>
</tr>
<tr>
<td>Cognitive interventions</td>
<td>To change misunderstandings regarding sleep</td>
<td>Patient’s dysfunctional beliefs and attitudes about sleep are identified; patient is educated to change these beliefs and attitudes, including both normal changes in sleep with age and changes that are pathologic.</td>
</tr>
<tr>
<td>Relaxation techniques</td>
<td>To recognize and relieve tension and anxiety</td>
<td>In progressive muscle relaxation, patient is taught to tense and relax each muscle group; in electromyographic biofeedback, patient is given feedback regarding muscle tension and learns techniques to relieve it; meditation or imagery techniques are taught to relieve racing thoughts or anxiety.</td>
</tr>
<tr>
<td>Cognitive-behavioral therapy</td>
<td>Combines features of several behavioral interventions</td>
<td>Typically combines stimulus control, sleep restriction, and cognitive interventions, with or without relaxation techniques.</td>
</tr>
<tr>
<td>Bright light</td>
<td>To correct circadian rhythm causes of sleeping difficulty (ie, sleep-phase problems)</td>
<td>Patient is exposed to sunlight or a light box. For delayed sleep phase, 2 hours early morning light; for advanced sleep phase, 2 hours evening light; light intensity &gt;2,000 lux. Appropriate timing of the light exposure is important. Shorter durations may be as effective. Routine eye examination is recommended before treatment; do not use light boxes with ultraviolet exposure.</td>
</tr>
</tbody>
</table>
Nonpharmacologic Interventions (Cont’d)

- Behavioral treatment of insomnia is effective in older adults.
- Sleep hygiene is generally not effective for chronic insomnia when used alone.
- Improve sleep hygiene during the daytime:
  - Maintain a regular rising time and decrease or eliminate naps, unless necessary
  - Exercise daily but not within 2 hours before bedtime
  - Get adequate exposure to bright light during the day
  - Limit or eliminate alcohol, caffeine, nicotine especially within 4 hours of bedtime.
- Improve sleep hygiene at night:
  - Maintain a regular bedtime, unless not sleepy.
  - If hungry, have a light snack (except with symptoms of GERD or medical contraindications).
  - Avoid bright light exposure in the evening.
  - Relax mentally, wind down before bedtime, establish "worry-time" hours before bedtime, and maintain a routine period of preparation for bed.
  - Control the nighttime environment with comfortable cool temperature, quiet, and darkness.
  - Try a fan or other "white noise" machine.
  - Wear comfortable bed clothing.
  - If not asleep within 30 minutes, get out of bed and perform soothing activity (avoid bright light).

Pharmacologic Interventions

- Treat associated medical conditions.
- If possible, discontinue medications that contribute to sleep disturbances.
- Do not use antihistamines or sedating antipsychotics in routine management of insomnia.
- Use the smallest dosage of medication for the shortest duration necessary, and monitor for efficacy and adverse effects.
- Short-acting medications are recommended for patients with problems falling asleep.
- Intermediate-acting medications are recommended for patients with problems staying asleep.
- Discontinue sleep medications gradually.

### Medications Used for Insomnia in Older Adults

<table>
<thead>
<tr>
<th>Class, Medication</th>
<th>Starting Dose (Mg)</th>
<th>Usual Dose (Mg)</th>
<th>Half-Life (Hours)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intermediate-acting benzodiazepine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temazepam</td>
<td>7.5</td>
<td>7.5–30</td>
<td>8.8</td>
<td>Psychomotor impairment, increased risk of falls</td>
</tr>
<tr>
<td><strong>Short-acting non-benzodiazepines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eszopiclone</td>
<td>1</td>
<td>1–2</td>
<td>6</td>
<td>Reportedly effective for long-term use in selected individuals; may be associated with unpleasant taste, headache; may cause next-day mental impairment, risk of falls; avoid administration with high-fat meal</td>
</tr>
<tr>
<td>Zaleplon (a pyrazolopyrimidine)</td>
<td>5</td>
<td>5–10</td>
<td>1 (reportedly unchanged in older adults)</td>
<td>Can cause daytime drowsiness and dizziness; risk of falls</td>
</tr>
<tr>
<td>Zolpidem (an imidazopyridine)</td>
<td>5</td>
<td>5</td>
<td>1.5–4.5 (3 in older adults; 10 in hepatic cirrhosis)</td>
<td>Reportedly little daytime carryover, tolerance, or rebound insomnia; complicated sleep behaviors/parasomnias have been reported; risk of falls</td>
</tr>
<tr>
<td><strong>Melatonin receptor agonist</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramelteon</td>
<td>8</td>
<td>8</td>
<td>1.5 (2.6 in older adults)</td>
<td>Dizziness, myalgia, headache, other adverse events reported; no significant rebound insomnia or withdrawal with discontinuation</td>
</tr>
<tr>
<td><strong>Sedating antidepressants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mirtazapine (off-label)</td>
<td>7.5</td>
<td>7.5–45</td>
<td>31–39 in older adults; 13–34 in younger adults; mean = 21</td>
<td>Increased appetite, weight gain, headache, dizziness; daytime carryover; used for insomnia with depression</td>
</tr>
<tr>
<td>Trazodone (off-label)</td>
<td>25–50</td>
<td>25–150</td>
<td>Reportedly 6 ± 2; prolonged in older adults and obese individuals</td>
<td>Moderate orthostatic effects; administration after food minimizes sedation and postural hypotension; effective for insomnia with depression; risk of falls</td>
</tr>
</tbody>
</table>